Answers for organizations considering pharmaceutical, biotechnology, clinical research, healthcare facility or investor-advisory work with Ariba & Mac.
R&D, clinical/preclinical research, CMC and technology transfer, quality assurance, regulatory work, healthcare facility development, training, turnkey investor support and due diligence can be scoped separately or coordinated when the project dependencies require more than one discipline.
Yes. The site is positioned around Saudi Arabia, with offices shown in Jeddah and Madinah. Project scope can incorporate the applicable Saudi operating, SFDA, healthcare or facility requirements alongside international workstreams where needed.
Yes. A project does not need to replace existing partners. We can review the current responsibilities and evidence, identify gaps between organizations, and define the coordination or oversight needed to reach the next milestone.
We start with the decision or milestone you need to reach, the current project stage, available documents/data, target geography, known risks, third parties already involved and timeline expectations. The resulting scope defines assumptions, deliverables, responsibilities and decision gates.
No. We can support strategy, documentation, gap closure, readiness and authority interactions within the agreed scope, but approval decisions and review timelines remain with the relevant authority and depend on the quality and completeness of the underlying evidence.
Technical projects can identify information, technology and documentation dependencies, but formal legal, patent, freedom-to-operate, tax or other licensed professional opinions should be handled by the appropriately qualified adviser when required.
Yes. Due diligence can assess technical, regulatory, quality, commercial and execution assumptions before investment, while post-investment support can translate key findings into milestones, KPIs, risk owners and project-governance actions.
Send a concise project summary through the contact channel with the service or asset type, current stage, target market, available documentation and the decision you need to make next. That is enough to begin a focused scoping discussion.
The original role and recruitment questions are retained below for candidates.
Yes—you may apply for multiple roles if your qualifications align with each position’s requirements.
Yes—relocation assistance is available for qualified candidates moving to Saudi Arabia.
Research Scientists own scope and milestones, with regular reviews alongside R&D and leadership.
Yes—subject to IP/confidentiality review. We encourage scientific visibility and responsible publishing.
Yes—mentoring junior team members is part of the role, including training and code/data reviews.
Visit frequency is risk-based and protocol-dependent, aligned with ICH-GCP best practices.
Yes—hybrid approaches are used where appropriate to enhance quality and efficiency.
Yes—per policy and role level, including travel and accommodation where applicable.
Primarily EDC/eCRF, lab portals, and site SOP templates for documentation and logistics.
Yes—participant engagement and visit coordination are core parts of the role.
Yes—structured onboarding with SOPs, job shadowing, and regular check-ins with the site lead.
End-to-end regulatory lifecycle oversight from development through post-market activities.
Yes—hiring, training, and performance development may be core responsibilities as per role.
We align regulatory milestones with portfolio goals in concert with Clinical, CMC, and Commercial leads.
Primarily KSA and regional markets; global submissions based on program needs.
Standard eCTD compilation/publishing suites compliant with ICH specifications.
Yes—supporting queries, meetings, and commitments with relevant health authorities.
Diagnostics